Back to news

Anixa Biosciences and Curia will Develop Final Formulation for Breast Cancer Vaccine in Preparation for Phase 2 Clinical Trial

PR Newswire•18/11/2026•08:25 ET
0

Key Highlights

  • ➤Curia to develop stable, scalable formulation for Anixa’s breast cancer vaccine
  • ➤Anixa preparing breast cancer vaccine for Phase 2 clinical development
  • ➤Phase 1 enrolled 35 women and met primary endpoints
  • ➤74% of participants exhibited protocol-defined immune responses
  • ➤Curia formulation work targets future clinical studies and potential commercialization

Expert Statements

Amit Kumar, Chairman and CEO of Anixa Biosciences

“Selection of Curia is another important milestone as we prepare to advance our breast cancer vaccine into Phase 2 clinical development. Our Phase 1 trial demonstrated encouraging safety and immune-response results, and we are now focused on the activities necessary to support the next stage of clinical testing. Curia brings extensive expertise in pharmaceutical formulation and manufacturing processes, and we believe their capabilities will be valuable as we work toward developing a vaccine that could ultimately help prevent breast cancer.”

Ranald Baillie, VP, Drug Product Development and General Manager at Curia Glasgow

“Curia looks forward to providing formulation development support for Anixa's peptide cancer vaccine. Successful formulation and product development requires looking beyond the formulation itself to understand stability, analytical performance, scalability and the requirements of aseptic manufacturing. Curia's integrated expertise allows us to address those considerations early and develop robust processes designed to support Anixa as it advances this vaccine towards commercialization.”

Anixa Biosciences and Curia will Develop Final Formulation for Breast Cancer Vaccine in Preparation for Phase 2 Clinical Trial PR Newswire

Collaboration to support development of a stable, scalable formulation for clinical development and potential commercialization

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in